5:03 PM
 | 
Oct 25, 2013
 |  BC Extra  |  Company News

Biogen Idec gains on Tecfidera news

Biogen Idec Inc. (NASDAQ:BIIB) was up $3.04 to $252.26 on Friday after EMA's CHMP said it will "likely" make a decision in November on the new active substance (NAS) designation for multiple sclerosis drug

Read the full 160 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >